Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

1. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study Full Text available with Trip Pro

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation J Clin Oncol Actions . 2021 Apr 29;JCO2003488. doi: 10.1200/JCO.20.03488. Online ahead of print. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study , , , , , , , , , , , , , , , , , , , Affiliations Expand

2021 EvidenceUpdates

2. Hydrogel rectal spacer SpaceOAR in prostate cancer radiation therapy - Health economic evaluation

Hydrogel rectal spacer SpaceOAR in prostate cancer radiation therapy - Health economic evaluation Hydrogel rectal spacer SpaceOAR™ in prostate cancer radiation therapy - NIPH NIPH's website uses cookies. Read more about our use of cookies in our privacy policy. Search for: Søk Menu To top level Close Infectious diseases & Vaccines Mental & Physical health Environment & Lifestyle Health in Norway Quality & Knowledge Research & Access to data About NIPH Close Hydrogel rectal spacer SpaceOAR™ (...) in prostate cancer radiation therapy Subscribe me! You have subscribed to alerts about: Hydrogel rectal spacer SpaceOAR™ in prostate cancer radiation therapy Health technology assessment Hydrogel rectal spacer SpaceOAR™ in prostate cancer radiation therapy - Health economic evaluation Published 10.02.2021 We were commissioned to perform a health technology assessment of SpaceOAR™ hydrogel for prevention of radiation-induced side effects following treatment for prostate cancer. We were commissioned

2021 Norwegian Institute of Public Health

3. Abiraterone Accord - metastatic prostate cancer

Abiraterone Accord - metastatic prostate cancer Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. EMA/163793/2021 EMEA/H/C/005408 Abiraterone Accord (abiraterone acetate) An overview (...) of Abiraterone Accord and why it is authorised in the EU What is Abiraterone Accord and what is it used for? Abiraterone Accord is a cancer medicine used to treat men with metastatic prostate cancer. This is cancer that affects the prostate gland (a gland of the male reproductive system). It is used when the cancer has spread to other parts of the body (metastatic). Abiraterone Accord is used together with prednisone or prednisolone (anti-inflammatory medicines): • when the cancer is newly diagnosed, high

2021 European Medicines Agency - EPARs

4. Enzalutamide (Xtandi) for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)

Enzalutamide (Xtandi) for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT) Enzalutamide (Xtandi®) for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT) - Repository of AIHTA GmbH English | Browse - - - Enzalutamide (Xtandi®) for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC (...) ) in combination with androgen deprivation therapy (ADT) Grössmann, N. (2021): Enzalutamide (Xtandi®) for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). Oncology Fact Sheet Nr. 46. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 439kB Item Type: Oncology Fact Sheet Subjects: > > > > Language: English Series Name: Oncology Fact Sheet Nr. 46 Deposited on: 16 Apr 2021 13:17 Last

2021 Austrian Institute of Health Technology Assessment

5. MRI-US fusion targeted biopsy for diagnosis of prostate cancer

MRI-US fusion targeted biopsy for diagnosis of prostate cancer ACE Technology Guidances ACE Technology Guidances ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the subsidy status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the subsidy recommendations, and key clinical and economic evidence (...) which informed their deliberations. Published on 30 Apr 2021 Last Updated on 30 Apr 2021 Guidance Recommendation The Ministry of Health’s Medical Technology Advisory Committee has recommended: Magnetic resonance imaging-ultrasound (MRI-US) fusion targeted biopsy alone or combined with non-targeted biopsy may be considered for the initial diagnosis of prostate cancer in men aged 18 years or older: Who are suspected of having prostate cancer due to persistently elevated prostate-specific antigen (PSA

2021 ACE Technology Guidance (Singapore)

6. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer

TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several (...) management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation J Clin Oncol Actions . 2021 Apr 20;39(12):1371-1382. doi: 10.1200/JCO.20.02759. Epub 2021 Feb 22. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer

2021 EvidenceUpdates

7. Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen

Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen - Repository of AIHTA GmbH English | Browse - - - Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC (...) ) previously treated with a docetaxel containing regimen Grössmann, N. (2020): Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen. Oncology Fact Sheet Nr. 8. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 65kB Item Type: Oncology Fact Sheets Subjects: > > > > Language: English Series Name: Oncology Fact Sheet Nr. 8 Deposited on: 02 Jun 2020 16:06 Last

2021 Austrian Institute of Health Technology Assessment

8. Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial Full Text available with Trip Pro

Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search (...) for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Clinical Trial JAMA Netw Open Actions . 2021 Jan 4;4(1):e2034633. doi: 10.1001/jamanetworkopen.2020.34633. Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized

2021 EvidenceUpdates

9. Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer

Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer CUAJ – CUA Best Practice Report Shayegan et al BPR: PSMA PET in prostate cancer 1 © 2021 Canadian Urological Association Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic (...) resonance (MR) in prostate cancer Bobby Shayegan *1 ; Katherine Zukotynski *2 ; François Bénard 3,4 ; Cynthia Ménard 5 ; Golmehr Sistani 6 ; Glenn Bauman 7 ; Patrick Veit-Haibach 8 ; Ur Metser 9 1 Department of Urology, McMaster University, Hamilton, ON, Canada; 2 Departments of Medicine and Radiology, McMaster University, Hamilton, ON, Canada; 3 PET Functional Imaging, BC Cancer, Vancouver, BC, Canada; 4 Department of Radiology, University of British Columbia, Vancouver, BC, Canada; 5 Department

2021 Canadian Urological Association

10. Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer

Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer Guideline 27-2 Version 2 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario) Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer M.A. Haider, J. Brown, J. Chin, A. Loblaw, N. Perlis, N. Schieda, and the MPMRI in the Diagnosis of Clinically Significant Prostate Cancer Guideline Development Group (...) (Vancouver Style): Haider MA, Brown J, Chin J, Loblaw A, Perlis N, Schieda N. Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer. Toronto (ON): Ontario Health (Cancer Care Ontario); 2021 February 11. Program in Evidence-Based Care Guideline No.: 27-2 Version 2, available on the OH (CCO) website. Copyright This report is copyrighted by Ontario Health (Cancer Care Ontario); the report and the illustrations herein may not be reproduced without the express

2021 Cancer Care Ontario

11. Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update

Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Show account (...) displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation J Clin Oncol Actions . 2021 Jan 26;JCO2003256. doi: 10.1200/JCO.20.03256. Online ahead of print. Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Emory University, Atlanta, GA. 2 American Society of Clinical Oncology, Alexandria, VA. 3 Erasmus MC

2021 EvidenceUpdates

12. Olaparib (Lynparza) for metastatic castration-resistant prostate cancer (mCRPC)

Olaparib (Lynparza) for metastatic castration-resistant prostate cancer (mCRPC) Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC) - Repository of AIHTA GmbH English | Browse - - - Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC) Grössmann, N. (2020): Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC). Oncology Fact Sheet Nr. 23. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z

2021 Austrian Institute of Health Technology Assessment

13. Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID) Full Text available with Trip Pro

Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID) Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID) , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Southampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom. 2 University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom. 3 Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, United Kingdom. 4 Lancashire Teaching Hospitals NHS

2021 EvidenceUpdates

14. 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC)

2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC) CUAJ • February 2021 • Volume 15, Issue 2 © 2021 Canadian Urological Association CUA-CUOG GUIDELINE E81 Cite as: Saad F , Aprikian A, Finelli A, et al. 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J 2021;15(2):E81-9. http://dx.doi.org (...) modified Oxford Center for Evidence-Based Medicine grading system. Based on a modified GRADE methodology, the strength of each recommendation is represented by the words STRONG or WEAK. Introduction Castration-resistant prostate cancer (CRPC) is defined by dis - ease progression despite castrate levels of testosterone and may present as either a continuous rise in serum prostate- specific antigen (PSA) levels, the progression of pre-existing disease, and/or the appearance of new metastases. Advanced

2021 Canadian Urological Association

15. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER)

A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER) A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get (...) . A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER) , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Radiation Oncology, University of California, Los Angeles, CA, USA. 2 Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA. 3 Department of Medicine, Statistics Core, University of California, Los Angeles, CA, USA. 4 Department of Urology, Mayo Clinic, Rochester, MN, USA

2021 EvidenceUpdates

16. Relugolix (Orgovyx) - To treat advanced prostate cancer

Relugolix (Orgovyx) - To treat advanced prostate cancer Drug Approval Package: ORGOVYX U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ORGOVYX Company: Myovant Sciences GmbH Application Number: 214621 Approval Date: 12/18/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2021 FDA - Drug Approval Package

17. Gallium 68 PSMA-11 - For detection and localization of prostate cancer

Gallium 68 PSMA-11 - For detection and localization of prostate cancer Drug Approval Package: GALLIUM GA 68 PSMA-11 U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: GALLIUM GA 68 PSMA-11 Company: University of California Los Angeles Application Number: 212642 Approval Date: 12/01/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA

2021 FDA - Drug Approval Package

18. Apalutamide (Erleada) - for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)

Apalutamide (Erleada) - for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) Published 18 January 2021 Statement of advice SMC2323 apalutamide 60mg film-coated tablets (Erleada®) Janssen-Cilag Ltd 4 December 2020 ADVICE: in the absence of a submission from the holder of the marketing authorisation apalutamide (Erleada®) is not recommended for use within NHSScotland. Indication under review: in adult men for the treatment of metastatic hormone-sensitive prostate cancer

2021 Scottish Medicines Consortium

19. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID (...) : 10.1016/j.eururo.2020.09.042. Epub 2020 Nov 7. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Urology, University Hospital, St. Etienne, France. Electronic address: nicolas.mottet@chu-st-etienne.fr. 2 Department of Urology, St. Antonius Hospital, Utrecht, The Netherlands. 3 Hasselt, Belgium. 4 Department

2021 EvidenceUpdates

20. Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis Full Text available with Trip Pro

Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) 2;3(11):e2025826. doi: 10.1001/jamanetworkopen.2020.25826. Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis , , , , , Affiliations Expand Affiliations 1 Division of Medical Oncology, Department of Internal Medicine, University of Kentucky, Lexington. 2 Markey Cancer Center, University of Kentucky, Lexington. 3 University of Kentucky College of Pharmacy, Lexington. PMID: 33201234 PMCID: DOI: Free PMC

2021 EvidenceUpdates